TORONTO, May 31, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated medical cannabis leader with core operations in
Latin America and Europe, is pleased to announce that the
Company´s management will be participating in the following
investor:
Jefferies Healthcare Conference
Date:
June 2nd, 2021
Time: 4:00pm ET
To register: https://wsw.com/webcast/jeff174/khrn/1858869
Benzinga Virtual Cannabis Capital Conference
- Panel Discussion: The Companies Driving International Market
Growth
Date: Thursday,
June 3rd, 2021
Time: 1:15pm ET
- Corporate Presentation
Date: Thursday, June 3rd, 2021
Time: 1:55pm ET
To register:
https://events.benzinga.com/squeeze-page-422415971607984646162
Cantor Fitzgerald International Cannabis
Forum
Date: June
28th, 2021
Time: 11:00am ET
To register:
https://zoom.us/webinar/register/WN_V-xX3gY5SxKKSSNOHQnlSw
To receive additional information, request an invitation, or
schedule a one-on-one meeting with Khiron management, please
contact your Conference representative or the Company's investor
relations team at investors@khiron.ca
Recent Company Highlights:
- Insurance coverage in Colombia
continues to be a catalyst for growth, with more than 7,500
prescriptions filled in Q1 2021 and over 19,000 prescriptions
filled to date. With continued month-over-month growth, Q2 2021
continues to build on the achievements of Q1 2021.
- Insurance coverage continues to improve patient access to
medical cannabis, with the percentage of prescriptions issued and
covered by insurance increasing from over 40% in Q4 2020 to over
60% in Q1 2021.
- Returning medical cannabis patients in Colombia reached nearly 50% in Q1 2021, as
compared to approximately 20% in Q3 2020, providing a more stable
Medical Cannabis revenue base.
- Khiron real-world evidence is improving physician engagement,
patient outcomes and strategic decision-making; initial results
show significant benefits to quality of life, as well as
significant cost benefit to key insurance clients.
- In March 2021, Khiron commenced
sales in Germany with the
successful delivery of EU-GMP medical cannabis products. Khiron
1/14 (High CBD flower) has been used to treat indications such as
anxiety, substance-use disorder and migraines.
- The Company continues to advance its operations in the UK. In
April 2021, the Company introduced
Khiron 1/14 (High CBD flower) in addition to 5-gram jars of flower
products. In addition, the Company's medical cannabis e-learning
certification, Khiron Academy, recently received accreditation for
Continuing Professional Development credits in the UK.
Grants of Options and Restricted Share Units:
The Company also announces the award of stock options
("Options") and restricted share units ("RSUs") under the Company's
amended and restated RSU and Option plans on May 31, 2021, to the following executive
officers:
Name
|
Title/Position
|
Number of Options
or RSUs
|
Exercise Price,
Vesting Schedule and Expiry Date
|
Juan Diego
Alvarez
|
VP
Regulatory
|
70,500
RSUs
|
RSU Vesting
Schedule:
10% on the Grant
Date
15% 6 months after
the Grant Date
25% 12 months after
the Grant Date
25% 18 months after
the Grant Date
25% 24 months after
the Grant Date
Expiry
Date: December 15, 2024
|
Manuel
Buendia
|
VP
Operations
|
75,000
RSUS
|
Rodrigo
Duran
|
VP Pharma
|
85,000
RSUs
|
Elsa
Navarro
|
VP Marketing &
Communications
|
59,000
RSUs
|
Franziska
Katterbach
|
Chief Legal Officer
and Managing Director, Khiron Europe
|
1,400,000
Options
600,000
RSUS
|
Option Exercise
Price: $0.75 per share
Option Vesting
Schedule:
533,334 on the Grant
Date
266,667 on November
27, 2021
600,000 on or before
December 31, 2021, conditional on achievement of specific
performance targets
Option Expiry
Date: May 31, 2026
RSU Exercise
Price: Not applicable
600,000 RSUs vest
achievement of specific performance targets on or before December
31, 2021
RSU Expiry
Date: December 15, 2024
|
Tejinder
Virk
|
President and
Managing Director, Khiron Europe
|
1,400,000
Options
600,000
RSUS
|
|
TOTAL
Options
TOTAL
RSUs
|
2,800,000
1,489,500
|
|
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru, Germany
and the United Kingdom, and is
positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing Products unit
launched the first branded CBD skincare brand in Colombia, with Kuida™ now marketed in multiple
jurisdictions in Latin America,
the US and United Kingdom. The
Company is led by Co-founder and Chief Executive Officer,
Alvaro Torres, together with an
experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-upcoming-investor-events-and-grant-of-options-and-restricted-share-units-301302479.html
SOURCE Khiron Life Sciences Corp.